Last checked at 28 May 2013 07:00
Tissue Regenix Group plc
Appointment of Orthopaedics Business Development Manager
YORK, 28 May, 2013 - Tissue Regenix Group plc ("Tissue Regenix" or "the Group") (AIM:TRX), the regenerative medical devices company, announces the appointment of Peter Hamer as Business Development Manager of its Orthopaedics division, with immediate effect.
Peter will be responsible for leading the development of sales and marketing activity of the Group's Orthopaedics product range, including Tissue Regenix's meniscus treatment, as it continues to develop through to full commercialisation.
Peter joins Tissue Regenix from Corin Group, a world leader in the development, production and distribution of reconstructive orthopaedic devices, where he held the role of Commercial Director UK and Export, leading all Export Sales Territories through third party distributor networks as well as for the entire Corin Group UK subsidiary sales and marketing business and customer services department. Peter has over 20 years of sales and marketing experience, 12 years of which have been in senior management roles, and he has held roles at companies including Biomet and Allergan among others.
Antony Odell, Managing Director of Tissue Regenix, said:
"Peter's appointment is another important step in building our senior management team as we enter the next phase of the Group's development and move towards full commercialisation of our Orthopaedics product range. Peter's extensive experience in taking orthopaedic products to market reiterates the good progress we are making in delivering on our strategy."
Approximately 1.5 million meniscal procedures are performed each year in the US and Europe and the market offers considerable opportunity for Tissue Regenix's products, both domestically and internationally, while the Group also expects its ligament repair product to begin preclinical trial in 2014.
For additional information please contact:
Tissue Regenix Group plc | +44 (0)1904 435 176 |
Antony Odell, Managing Director Ian Jefferson, Chief Financial Officer | |
Jefferies International Ltd. | +44 (0)20 7029 8000 |
Simon Hardy Harry Nicholas | |
Newgate Communications | +44 (0)20 7680 6550 |
Alistair Kellie Andrew Adie Andrew Jones |
About Tissue Regenix
Tissue Regenix (AIM: TRX) is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®) technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient's body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.
Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds. The company commercialises academic research conducted by our partners around the world.